FCH
NVCR icon

Freestone Capital Holdings’s NovoCure NVCR Stock Holding History

Freestone Capital Holdings’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15
Closed -$2.6K – 870
2020
Q4 		$2.6K Sell
15
-33
-69% -$4.52K ﹤0.01% 1100
2020
Q3 		$5.34K Buy
+48
New +$3.84K ﹤0.01% 868

Other funds holding NVCR

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Freestone Capital Holdings's NVCR Position: Q1 2021 in Review

Freestone Capital Holdings sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 15 shares — an estimated $2.6K sold.

Freestone Capital Holdings first reported a position in NVCR in Q3 2020 and held it in 2 quarters. The position peaked at $5.34K in Q3 2020. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

  • Freestone Capital Holdings reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
  • Freestone Capital Holdings sold 15 NovoCure shares in Q1 2021, an estimated $2.6K.
  • Freestone Capital Holdings first reported a position in NovoCure in Q3 2020 and held it in 2 quarters.
  • Freestone Capital Holdings's NovoCure position peaked at $5.34K in Q3 2020.
  • 327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Freestone Capital Holdings's 13F filing for Q1 2021, filed 17 May 2021.